Seubert, Peter

Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.

C F Lippa; J E Duda; M Grossman; H I Hurtig; D Aarsland; B F Boeve; D J Brooks; D W Dickson; B Dubois; M Emre; et al. (Profiled Authors: Growdon, John H; Hardy, John; Dickson, Dennis; McKeith, Ian G; Masliah, Eliezer; Galasko, Douglas; Lee, Virginia M-Y; Trojanowski, John Q; Grossman, Murray; Iwatsubo, Takeshi)

Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. clippa@drexelmed.edu
Neurology 2007;68(11):812-9.

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of alpha-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal alpha-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of alpha-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for alpha-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

2 Originating Grant

• 1.

  TROJANOWSKI, JOHN Q.

  Alzheimer's Disease Core Center

  15 July 1997 - 30 June 2016

  NATIONAL INSTITUTE ON AGING

  Total Funding: $ 25,158,594

• 2.

  Trojanowski, John Q

  Molecular substrates of aging and neuron death

  15 May 1997 - 30 April 2010

  NATIONAL INSTITUTE ON AGING

  Total Funding: $ 24,601,856

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.